Results 181 to 190 of about 2,306,523 (240)

Neurocardiology: Brain–Heart Interactions in the Heart

MedComm, Volume 7, Issue 9, September 2026.
The heart and brain maintain systemic homeostasis through bidirectional communication involving neural, biochemical, and mechanical pathways. Dysregulation of these pathways contributes to a spectrum of conditions involving heart–brain interactions, including Takotsubo syndrome, the epileptic heart, stroke–heart syndrome, heart failure, cardiac ...
Wentao Wang, Hao Jia, Han Han, Jiangping Song   +3 more
wiley   +1 more source

Bidirectional crosstalk between the nervous system and the tumour microenvironment: mechanisms, feedback loops and therapeutic opportunities. [PDF]

Front Cell Dev Biol
Kuang G, Qiu Z, Li L, Ji H, Liu Y.
europepmc   +1 more source

Cancer Neuroscience: From Local Neuro–Immune Microenvironments to Systemic Brain–Body Circuitry

MedComm, Volume 7, Issue 9, September 2026.
This review outlines the cancer neuroscience paradigm, spanning systemic brain–body circuitry and local neuro–immune–tumor microenvironments. We discuss how tumors promote axonogenesis and pseudo‐synapse formation, and how sensory neuropeptides, such as CGRP, contribute to CD8+ T‐cell exhaustion.
Mingxuan Xie, Yu Zhao, Xinruo Xing, Yuqiang Liu, Jungang Zhao, Maojin Yao, Jun Tang, Jianzhu Zhao   +7 more
wiley   +1 more source

Association of Functional <i>ADRB1</i> (rs1801252) and <i>ADRB2</i> (rs1042714) Polymorphisms with Primary Open-Angle Glaucoma in a Saudi Cohort. [PDF]

Int J Mol Sci
Kondkar AA, Sultan T, Azad TA, Osman EA, Almobarak FA, Alsirhy EY, Al-Obeidan SA.   +6 more
europepmc   +1 more source

Identification of Predictive Signatures for Osimertinib‐Associated Interstitial Lung Disease: Integrating Ensemble Machine Learning and Temporal Dynamics

Medicine Bulletin, Volume 2, Issue 4, Page 352-363, September 2026.
ABSTRACT The shift toward chronic management of EGFR‐mutant lung cancer underscores the urgent need to identify molecular features potentially relevant to osimertinib‐associated interstitial lung disease (ILD). This study aimed to investigate candidate molecular mechanisms of this toxicity by integrating putative osimertinib target profiles with ILD ...
Yilin Ye, Lianxin Zhu, Yunxiang Xie, Peng Sun, Cui Chen, Zhihua Zhu   +5 more
wiley   +1 more source

<i>LRP4</i>-Related Congenital Myasthenic Syndrome: Clinical, Pathophysiological, and Therapeutic Aspects. [PDF]

Muscles
Azeka FYK, Serrano PL, Seneor DD, Calegaretti SL, Pinheiro MM, Martins MV, Guilherme LM, Barile JP, Mendes PM, Garcia LHMR, Galvão MJTC, Gama SM, Cavalheiro RBR, Farias IB, Machado RIL, Pinto WBVR, Oliveira ASB, Sgobbi P.   +17 more
europepmc   +1 more source

AGRN‐, LRP4‐, MUSK‐Related CMS: Clinical, Neurophysiological, Morphological, Genetic and Pathological Mechanisms

Muscle &Nerve, Volume 74, Issue S1, Page S31-S40, September 2026.
ABSTRACT Congenital myasthenic syndromes (CMS) are inherited disorders caused by mutations in genes encoding proteins essential for neuromuscular junction (NMJ) function. Pathogenic variants have been identified in more than 35 genes, underscoring the complexity of synaptic biology and the wide range of mechanisms that can compromise neuromuscular ...
Rocio‐Nur Villar‐Quiles, Damien Sternberg, Marie‐Christine Nougues, Arnaud Isapof, Bruno Eymard, Stéphanie Bauché   +5 more
wiley   +1 more source

Neural regulation of immune evasion in breast cancer: a multiscale neuro-immune framework. [PDF]

Front Immunol
Li X, Gong X, Cong Y, Wang J, Li Y, Chen G, Li Y, Qiao G.   +7 more
europepmc   +1 more source

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms

Muscle &Nerve, Volume 74, Issue S1, Page S52-S57, September 2026.
ABSTRACT The congenital myasthenic syndromes are rare disorders of impaired signal transmission at the neuromuscular junction. Despite next generation sequencing facilitating the identification of variants in myasthenic‐associated genes, these variants are frequently of unknown significance and the clinical diagnosis can be delayed.
David Beeson
wiley   +1 more source

Recent advances in the development of GRK2 inhibitors: blocking the interaction of GRK2 with its partners. [PDF]

Acta Pharmacol Sin
Han CC, Guo HZ, Guo FY, Tan HZ, Sun HZ, Gu JT, Zuo SJ, Wang WK, Ma Y, Wei W.   +9 more
europepmc   +1 more source